Many patients expect CINV
to be a distressing part of chemotherapy, and their symptoms often occur outside of the clinic.
Its management has been refined over the past several decades, but despite the existence of effective treatments and clear antiemetic guidelines, many patients still suffer from CINV
, particularly during the delayed phase after chemotherapy.
The report, Global CINV
Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.
AKYNZEO is a new oral fixed combination that targets two critical signaling pathways associated with CINV
, by combining netupitant, an NK1 receptor antagonist, with palonosetron (brand name: ALOXI), a 5-HT3 receptor antagonist.
Authors concluded that the ginger root powder was effective in reducing the severity of acute and delayed CINV
as an additional therapy to ondensetron and dexamethasone in patients receiving high emetogenic chemotherapy.
Significant strides were made in the 1990s for the treatment of CINV
with the advent of selective 5-H[T.
The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV
and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV
," said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX.
In the phase 2 and phase 3 clinical trials NEPA demonstrated that it provides a significant improvement in the prevention of acute and delayed CINV
when compared to oral palonosetron.
The product showed to be effective in preventing both acute and delayed CINV
in patients receiving emetogenic chemotherapies.
Studies show that patients often receive antiemetic drug regimens that are inconsistent with CINV
treatment guidelines, which call for multiple-pathway targeted antiemetic prophylaxis.
Seventy-Two Percent of Surveyed MCOs Expect to Introduce Bundled Payments for CINV
Drugs This Year or Within the Next Three Years, According to a New Report from Decision Resources
In clinical trials in paediatric patients, CINV
frequency varied from 35 to 80 percent depending on the age of the patient, the site of tumour and the type of chemotherapy given.